title: Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Boston, MA mizuki_nishino@dfci.harvard.edu.
authors.forename: Mizuki
authors.initials: M
authors.lastname: Nishino
authors.forename: Lynette M
authors.initials: LM
authors.lastname: Sholl
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Hiroto
authors.initials: H
authors.lastname: Hatabu
authors.forename: Nikhil H
authors.initials: NH
authors.lastname: Ramaiya
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D000077594:Nivolumab; D011014:Pneumonia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D011859:Radiography
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab